ES2171156T3 - Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas. - Google Patents

Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas.

Info

Publication number
ES2171156T3
ES2171156T3 ES90914669T ES90914669T ES2171156T3 ES 2171156 T3 ES2171156 T3 ES 2171156T3 ES 90914669 T ES90914669 T ES 90914669T ES 90914669 T ES90914669 T ES 90914669T ES 2171156 T3 ES2171156 T3 ES 2171156T3
Authority
ES
Spain
Prior art keywords
genetic engineering
aids
retrovirical
diseases
vaccine production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914669T
Other languages
English (en)
Inventor
Joel Haynes
Michel Henri Klein
Benjamin Rovinski
Shi Xian Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd, Aventis Pasteur SA filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of ES2171156T3 publication Critical patent/ES2171156T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA PARTICULA, TIPO-RETROVIRUS, INMUNOGENICA QUE NO ES INFECCIOSA Y QUE ES UTIL COMO COMPONENTE CANDIDATO A UNA VACUNA PARA LAS INFECCIONES RETROVIRALES, INCLUYENDO EL SIDA Y ATLL, SE PRODUCE MEDIANTE INGENIERIA GENETICA.
ES90914669T 1989-10-13 1990-10-12 Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas. Expired - Lifetime ES2171156T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898923123A GB8923123D0 (en) 1989-10-13 1989-10-13 A vaccine for human immunodeficiency virus

Publications (1)

Publication Number Publication Date
ES2171156T3 true ES2171156T3 (es) 2002-09-01

Family

ID=10664542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914669T Expired - Lifetime ES2171156T3 (es) 1989-10-13 1990-10-12 Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas.

Country Status (10)

Country Link
US (5) US5439809A (es)
EP (1) EP0495811B1 (es)
JP (1) JP2537570B2 (es)
AT (1) ATE211766T1 (es)
CA (1) CA2067333C (es)
DE (1) DE69033896T2 (es)
DK (1) DK0495811T3 (es)
ES (1) ES2171156T3 (es)
GB (1) GB8923123D0 (es)
WO (1) WO1991005864A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
KR920703639A (ko) * 1989-11-20 1992-12-18 온코겐 리미티드 파트너쉽 항-바이러스제와 이뮤노겐으로 유용하게 사용되는 비-복제성 리콤비넌트 레트로바이러스 물질
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5912338A (en) * 1990-10-12 1999-06-15 Benjamin Rovinski Nucleic acids encoding self-assembled, non-infectious, non-replicating, immunogenic retrovirus-like particles comprising modified HIV genomes and chimeric envelope glycoproteins
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
AU702634B2 (en) * 1991-03-07 1999-02-25 Virogenetics Corporation Immunodeficiency recombinant poxvirus
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
US6268211B1 (en) 1991-08-20 2001-07-31 L'institut De Recherches Cliniques De Montreal Non-infectious HIV transgene
EP0588816A1 (en) * 1991-05-15 1994-03-30 Institut De Recherches Cliniques De Montreal Transgenic non-human animal carrying a non-infectious hiv genome
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
JPH06261764A (ja) * 1993-02-17 1994-09-20 Wisconsin Alumni Res Found 混合型ｌｔｒ含有超複合型レトロウイルス及びその使用方法
US5470572A (en) * 1993-07-16 1995-11-28 University Of Puerto Rico Non-infectious simian immunodeficiency virus particles produced by cell line CRL 11393
AU7568794A (en) * 1993-08-20 1995-03-21 St. Luke's-Roosevelt Hospital Center Hiv (vif)-related compositions, and prophylactic and therapeutic uses thereof
US6015661A (en) * 1994-02-14 2000-01-18 The Macfarlane Burnet Centre For Medical Research Limited Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
US5858838A (en) 1998-02-23 1999-01-12 Taiwan Semiconductor Manufacturing Company, Ltd. Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
EP0850069B1 (en) * 1994-11-15 2002-04-03 Powderject Vaccines, Inc. Method for inducing humoral and cellular immune responses utilizing intracellular delivery of peptide-coated microparticles
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
DE69739645D1 (de) * 1996-01-29 2009-12-17 Monogram Biosciences Inc Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening
US6024965A (en) * 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US6271354B1 (en) 1997-04-03 2001-08-07 Thomas Jefferson University Chimeric viral proteins
US6696289B1 (en) * 1997-08-07 2004-02-24 Creagene Inc. Replication-competent recombinant Sabin type 1 strain of poliovirus
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
WO1999058726A1 (en) 1998-05-12 1999-11-18 Genecure Llc Replication defective hiv vaccine
CA2338886C (en) * 1998-08-04 2011-10-04 Gerald V. Quinnan, Jr. Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
US7090848B1 (en) * 1998-08-04 2006-08-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
US6764676B1 (en) 1998-08-24 2004-07-20 Pfizer Inc. Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CA2401974C (en) 2000-03-02 2013-07-02 Emory University Dna expression vectors and methods of use
EP1776961A1 (en) * 2000-04-27 2007-04-25 Sanofi Pasteur Limited Immunizing against HIV infection
AU2001254561A1 (en) * 2000-04-27 2001-11-12 Aventis Pasteur Limited Immunizing against hiv infection
US6461616B1 (en) * 2000-09-09 2002-10-08 Akzo Nobel Nv EIAV p26 deletion vaccine and diagnostic
US6585978B1 (en) * 2000-09-09 2003-07-01 Akzo Nobel EIA vaccine and diagnostic
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
DE60234018D1 (de) * 2001-03-08 2009-11-26 Univ Emory Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
US7943146B2 (en) * 2001-12-21 2011-05-17 Myrexis, Inc. Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface
EP1590432A4 (en) * 2003-01-15 2008-05-14 Res Inst For Genetic And Human DNA COMPOSITION AND ITS USE
JP2007505130A (ja) * 2003-09-09 2007-03-08 バイレクシス コーポレイション ヒトにおいてｈｉｖに対する免疫応答を生成するための、レンチウイルスベクターベースのアプローチ
US20050222068A1 (en) 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US20090239215A1 (en) * 2004-12-16 2009-09-24 Brandeis University Clonable Tag for Purification and Electron Microscopy Labeling
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2009049350A1 (en) * 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
CA2746508A1 (en) 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US9839684B2 (en) 2011-04-06 2017-12-12 Biovaxim Limited Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2814847B1 (en) 2012-02-16 2018-04-18 VLP Therapeutics, LLC Virus like particle composition
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US9730996B2 (en) * 2012-10-24 2017-08-15 Texas Biomedical Research Institute Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
WO2016038895A1 (en) 2014-09-11 2016-03-17 Vlp Therapeutics, Llc Flavivirus virus like particle
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59104325A (ja) * 1982-12-07 1984-06-16 Japan Found Cancer ヒト白血病ウイルスの遺伝子ｒｎａに相補性を示すｄｎａ
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4752565A (en) * 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
WO1988003562A1 (en) * 1986-11-01 1988-05-19 Oxford Gene Systems Limited Particulate hybrid hiv antigens
JPH01120284A (ja) * 1987-11-05 1989-05-12 Shiro Kato Ｈｉｖ不完全粒子および該製造方法
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5019752A (en) 1988-06-16 1991-05-28 Hughes Aircraft Company Plasma switch with chrome, perturbated cold cathode
JPH02203783A (ja) * 1989-02-02 1990-08-13 Banyu Pharmaceut Co Ltd 抗原性を有する非感染性エイズウイルス産生クローン化ヒトｔ細胞
JP3140757B2 (ja) * 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
JP3034025B2 (ja) * 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド 自己アセンブルド欠損非自己増殖性ウイルス粒子
JP2897295B2 (ja) * 1989-12-14 1999-05-31 味の素株式会社 レトロウィルス高生産用ｄｎａ構築物及びレトロウィルス高生産用細胞株
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles

Also Published As

Publication number Publication date
DE69033896D1 (de) 2002-02-14
US6291227B1 (en) 2001-09-18
EP0495811B1 (en) 2002-01-09
US5439809A (en) 1995-08-08
US7008784B1 (en) 2006-03-07
EP0495811A1 (en) 1992-07-29
US5985641A (en) 1999-11-16
US5571712A (en) 1996-11-05
JP2537570B2 (ja) 1996-09-25
DK0495811T3 (da) 2002-02-11
WO1991005864A1 (en) 1991-05-02
DE69033896T2 (de) 2002-11-14
CA2067333C (en) 2001-05-01
JPH04506301A (ja) 1992-11-05
ATE211766T1 (de) 2002-01-15
CA2067333A1 (en) 1991-04-14
GB8923123D0 (en) 1989-11-29

Similar Documents

Publication Publication Date Title
ES2171156T3 (es) Produccion de vacunas por ingenieria genetica para sida y otras enfermedades retroviricas.
NO176766C (no) Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
ES2043752T3 (es) Procedimiento para la produccion biologica de amidas.
PT626998E (pt) "producao de plantas resistentes aos virus, mediante introducao de uma molecula de arn viral nao traduzivel e de sentido codificador"
MX9304027A (es) Variante de al enzima lipasa y metodo para su produccion.
DOP1960000898A (es) Metodo para hace hojas de rasurar.
DE60321318D1 (de) Gewinnung von delta-9 tetrahydrocannabinol
BR7400159D0 (pt) Processo para fabricar, a partir do po de uma liga, um artigo denso
DK489686A (da) Fremgangsmaade til fremstilling af 2-keto-l-gulonsyre
DE69021455D1 (de) Verfahren zur Herstellung von Ascorbinsäure.
ES2057191T3 (es) Metodo de produccion para una composicion que contiene proteinas.
ES2074053T3 (es) Procedimiento para la produccion de acido bishomo-gamma-linolenico.
YU99090A (sh) Postupak za dobijanje novih sojeva s. avermitilis
PT90030A (pt) Processo para a preparacao de liofilisado de ifosfamida e mesna
DE69230180D1 (de) Neuartige hefestämme zur herstellung von xylitol
ES2074431T3 (es) Un procedimiento para la sintesis de amicacina.
PT81647B (pt) Processo para a obtencao da enzima lenhinolitica por cultura de microorganismos da estirpe phanerochaete chrysosporium
ES2064082T3 (es) Proteinas bcrf1 como inhibidores de interferon-gamma.
YU46561B (sh) Postupak za stabilizaciju vodenog rastvora ranitidina
PT81970B (pt) Processo para a preparacao de um reagente para a dosagem, por hemaglutinacao, de anticorpos contra as toxinas bacterianas
DK0433428T3 (da) Hidtil ukendt stabil form af cephradin, fremgangsmåde til fremstilling deraf og mellemprodukter anvendt derved
DK0592685T3 (da) Plante, som er resistent over for to eller flere vira, og fremstilling deraf
ES475593A1 (es) Procedimiento de obtencion de un producto biologico extraido de un cultivo de hongos.
BR7807290A (pt) Plasmideo,processo para producao de um polipeptido especifico veiculo clonal,cultura bacteriana transformante,processo para produzir uma substancia imunogenica processo para preparar um gene estrutural,e polidesoxirribonucleotido de faixa dupla
ES2074257T3 (es) Derivados de aminoacidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 495811

Country of ref document: ES